References
- Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94
- Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014;21:1063–8
- Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: Results from an international survey on vaginal atrophy. Maturitas 2010;67:233–8
- Nappi RE, Kokot-Kierepa M. Vaginal health: Insights, views & attitudes (VIVA)–results from an international survey. Climacteric 2012;15:36–44
- Krychman M, Kingsberg S. REVEAL: revealing vaginal effects at mid-life: surveys of postmenopausal women and health care professionals who treat postmenopausal women. (Personal Communication) 2016
- Simon JA, Kokot-Kierepa M, Goldstein J, et al. Vaginal health in the United States: results from the Vaginal Health: insights, Views & Attitudes survey. Menopause 2013;20:1043–8
- Kingsberg S, Krychman M, Graham S, et al. The Women’s EMPOWER Survey: Identifying women’s perceptions on vulvar and vaginal atrophy (VVA) and its treatment. J Sex Med 2017;14:413–24
- Constantine G, Simon JA, Pickar JH, et al. The REJOICE trial: A phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause 2017;24:409–16
- Archer DF, Constantine GD, Simon J, et al. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause 2017;24:510–16
- Kingsberg S, Kroll R, Goldstein I, et al. Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR. Menopause 2017;24:894–9
- Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015;18:233–40
- Constantine GD, Bouchard C, Pickar JH, et al. Consistency of effect with a low-dose, estradiol vaginal capsule (TX-004HR): evaluating improvement in vaginal physiology and moderate-to-severe dyspareunia in subgroups of postmenopausal women. J Womens Health 2017;26:616–23
- Kingsberg S, Derogatis L, Simon JA, et al. TX-004HR improves sexual function as measured by the female sexual function index in postmenopausal women with vulvovaginal vulvar and vaginal atrophy: the REJOICE Trial. J Sex Med 2016;13:1930–7
- Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med 2018;178:681–90
- Pinkerton JV, Kaunitz AM, Manson JE. Not time to abandon use of local vaginal hormone therapies. Menopause 2018;25:855–8
- Diem SJ, Guthrie KA, Mitchell CM, et al. Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial. Menopause 2018;25:1086–93
- Pickar JH, Amadio JM, Bernick BA, et al. Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule. Climacteric 2016;19:181–7
- Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 2016;19:188–97
- Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10:1790–9
- The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Committee Opinion No. 659. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;127:e93–e96
- Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902